Odds of Sarepta Drug Approval Rise Sharply
Shares of Sarepta Therapeutics went through the roof Monday morning following an announcement that it plans to have a New Drug Application filed with the FDA by the end of 2014 for its muscular…
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 291J.P. Morgan’s Top Biotech and Health Care Picks With Huge Upside
In a new research report, the J.P. Morgan health care team highlights their top names to buy after the sell-off that may provide investors some incredible outsized gains over the rest of the year.
Obamacare Sign-Ups Top 8 Million
ThinkstockAt a press conference on Thursday afternoon, President Obama announced that the number of Americans using the public exchanges to enroll in a health insurance plan rose to 8 million after the deadline passed…
UnitedHealth Group Revenues Stung by Obamacare
UnitedHealth Group reported better-than-expected first-quarter earnings before markets opened Thursday, but revenues fell short of consensus estimates.
Medical Device Maker’s IPO a Modest Success
ThinkstockSome initial public offerings (IPOs) are considered a huge success if the stock appreciates more than about 20% on its IPO date. To some, though, that’s an unsuccessful launch from the company’s point of…
Why Lpath Could Rise 300%
Canaccord Genuity is one of the few firms that are willing to cover small-cap biotech and emerging pharma stocks. Sometimes the price target upside is off the charts as well. In case of Lpath…
Johnson & Johnson Earnings Point to New 52-Week High
Johnson & Johnson reported better-than-expected first-quarter results before markets opened Tuesday morning. And the company boosted its earnings guidance for the full year.
Gilead Risks Beyond Just Merck: Serious Chart Violation Watch
Gilead Sciences may have been largely responsible for the drop in biotech stocks after politicians went after its drug costs, but an excessive multiyear performance also allowed sellers to keep exiting the sector.
Who Bucked the Short Interest Trend in Biotech Stocks?
Thinkstock24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. Many biotech stocks pulled back in late March, and short sellers moved in on many of them. The largest…
Why Questcor Buyout Will Not Deter Short Sellers
The $5.6 billion acquisition of Questcor Pharmaceuticals by specialty drugmaker Mallinckrodt started the week off with a big bang. But just what did Mallinckrodt get?
FDA Keeps Driving Up Future Cost of Inhalable Insulin
While the FDA has been far from a friend to MannKind over the past few years, the latest FDA panel backing may have given diabetes patients and investors some hope. That hope was diminished…
Credit Suisse Says Grit Your Teeth and Buy Biotech
In a new report, the Credit Suisse team says large cap biotech is cheaper than the S&P 500 on 2016 and 2017 numbers. Here are the top biotech names rated Outperform at Credit Suisse.
Pancreatic Cancer Trial Enrollment Halt Damages Halozyme
Halozyme Therapeutics shares are getting pounded on Friday on news of a temporary halt of its Phase II trial enrollment and dosing for its pancreatic cancer study.
Stifel Says Strong Earnings Will Reignite Biotech Rally
ThinkstockWhen the biotech sell-off started in late February, the stocks had been market leaders for almost four years. The staggering and intense selling knocked a quick 17% off the index and immediately bearish voices…
Boulder Ranks as America’s Thinnest City
ThinkstockBoulder, Colo., ranked as the city least plagued by obesity, according to recent research. Among the 10 cities with the lowest level of obesity, another two also are in Colorado — Denver and Fort…